Immunocapture-liquid Chromatography/Mass Spectrometry in Simultaneous Quantification of Total Antibody and ADC for XMT-1522 in...
XMT-1522, an investigational antibody-drug conjugate (ADC) being developed by Mersana Therapeutics and Takeda, represents the first Dolaflexin®-based, cleavable ADC...
Trastuzumab Duocarmazine for Treatment of HER2-Expressing Breast Cancer
Trastuzumab duocarmazine* (SYD985; Synthon) is a novel antibody-drug conjugate composed of the recombinant humanized anti-epidermal growth factor receptor 2...
A Review of Cleavable Linkers
With 5 commercially available antibody-drug conjugates (ADCs) an nearly 100 novel agents in developments - from early discovery to...
New Reagents for the Rapid Generation of Efficacious Antibody-drug Conjugates
Because conjugation selectivity as well as stability and hydrophobicity of linkers and payloads drastically influence the performance and safety...
Anti-CD205 Antibody-Drug Conjugate MEN1309/OBT076 Shows Substantial in vitro Antitumor Activity
Non-clinical study findings published in the journal Molecular Cancer Therapeutics describing the characterization of the anti-CD205 antibody-drug conjugate (ADC)...
New Data Demonstrates Potential for RemeGen’s RC48 in HER2+ Cancers
Results from a robust oncology pipeline, including the latest phase II data of an investigational antibody-drug conjugates (ADC) called...
Sutro Presents Preliminary Results From Ongoing Phase I Study of STRO-001
California-based Sutro Biopharma has confirmed that the company will present preliminary results from the first 14 patients enrolled in...
Site Specific Conjugation of Hydrophobic Payloads Without Genetic Engineering
Site-specific conjugation leads to more homogeneous conjugates and allows control of the site of drug attachment. This approach frequently...
Understanding of the Underlying Mechanisms of Target-Independent Uptake and Toxicity
With 4 approved agents, antibody-drug conjugates or ADC have shown to be a very promising class of therapeutics.While the...
First-in-class Immunotherapeutic Approach Shows Efficacy in Neuroblastoma
Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to...
